181 related articles for article (PubMed ID: 12544505)
1. Positron emission tomography scanning in gynecologic and breast cancers.
Zimny M; Siggelkow W
Curr Opin Obstet Gynecol; 2003 Feb; 15(1):69-75. PubMed ID: 12544505
[TBL] [Abstract][Full Text] [Related]
2. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
Avril N; Dose J; Jänicke F; Ziegler S; Römer W; Weber W; Herz M; Nathrath W; Graeff H; Schwaiger M
J Natl Cancer Inst; 1996 Sep; 88(17):1204-9. PubMed ID: 8780629
[TBL] [Abstract][Full Text] [Related]
3. FDG PET and tumour markers in the diagnosis of recurrent and metastatic breast cancer.
Siggelkow W; Rath W; Buell U; Zimny M
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S118-24. PubMed ID: 15146295
[TBL] [Abstract][Full Text] [Related]
4. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures.
Schirrmeister H; Kühn T; Guhlmann A; Santjohanser C; Hörster T; Nüssle K; Koretz K; Glatting G; Rieber A; Kreienberg R; Buck AC; Reske SN
Eur J Nucl Med; 2001 Mar; 28(3):351-8. PubMed ID: 11315604
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of breast and gynecologic cancers by positron emission tomography.
Dehdashti F; Siegel BA
Semin Roentgenol; 2002 Apr; 37(2):151-68. PubMed ID: 12134368
[No Abstract] [Full Text] [Related]
6. [The value of F-18 fluorodeoxyglucose in positron emission tomography diagnosis of breast carcinoma].
Langsteger W; Jörg L; Tausch C; Heinisch M; Wieser B; Rechberger E; Panholzer PJ; Sega W; Aufschnaiter M
Wien Med Wochenschr; 2002; 152(11-12):255-8. PubMed ID: 12138651
[TBL] [Abstract][Full Text] [Related]
7. Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
Smith IC; Ogston KN; Whitford P; Smith FW; Sharp P; Norton M; Miller ID; Ah-See AK; Heys SD; Jibril JA; Eremin O
Ann Surg; 1998 Aug; 228(2):220-7. PubMed ID: 9712568
[TBL] [Abstract][Full Text] [Related]
8. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
[TBL] [Abstract][Full Text] [Related]
9. Positron emission tomography with fluorodeoxyglucose to evaluate tumor response and control after radiation therapy.
Chaiken L; Rege S; Hoh C; Choi Y; Jabour B; Juillard G; Hawkins R; Parker R
Int J Radiat Oncol Biol Phys; 1993 Sep; 27(2):455-64. PubMed ID: 8407422
[TBL] [Abstract][Full Text] [Related]
10. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management.
Greco M; Crippa F; Agresti R; Seregni E; Gerali A; Giovanazzi R; Micheli A; Asero S; Ferraris C; Gennaro M; Bombardieri E; Cascinelli N
J Natl Cancer Inst; 2001 Apr; 93(8):630-5. PubMed ID: 11309439
[TBL] [Abstract][Full Text] [Related]
11. Preoperative evaluation of prognosis in breast cancer patients by [(18)F]2-Deoxy-2-fluoro-D-glucose-positron emission tomography.
Inoue T; Yutani K; Taguchi T; Tamaki Y; Shiba E; Noguchi S
J Cancer Res Clin Oncol; 2004 May; 130(5):273-8. PubMed ID: 14986112
[TBL] [Abstract][Full Text] [Related]
12. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma.
Frilling A; Tecklenborg K; Görges R; Weber F; Clausen M; Broelsch EC
Ann Surg; 2001 Dec; 234(6):804-11. PubMed ID: 11729387
[TBL] [Abstract][Full Text] [Related]
13. [Role of [18F]-fluorodeoxyglucose positron emission tomography for the initial detection, staging, search for recurrences and restaging of gynaecological and breast cancers].
Grahek D; Barranger E; Daraï E; Uzan S; Talbot JN
Gynecol Obstet Fertil; 2005 Jun; 33(6):371-81. PubMed ID: 15927502
[TBL] [Abstract][Full Text] [Related]
14. The role of positron emission tomographic imaging in breast cancer.
McDonough MD; DePeri ER; Mincey BA
Curr Oncol Rep; 2004 Jan; 6(1):62-8. PubMed ID: 14664763
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum.
Whiteford MH; Whiteford HM; Yee LF; Ogunbiyi OA; Dehdashti F; Siegel BA; Birnbaum EH; Fleshman JW; Kodner IJ; Read TE
Dis Colon Rectum; 2000 Jun; 43(6):759-67; discussion 767-70. PubMed ID: 10859074
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic accuracy of FDG PET imaging for the detection of recurrent or metastatic gynecologic cancer.
Khan N; Oriuchi N; Yoshizaki A; Kanuma T; Higuchi T; Endo K
Ann Nucl Med; 2005 Apr; 19(2):137-45. PubMed ID: 15909494
[TBL] [Abstract][Full Text] [Related]
17. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group.
Wahl RL; Siegel BA; Coleman RE; Gatsonis CG;
J Clin Oncol; 2004 Jan; 22(2):277-85. PubMed ID: 14722036
[TBL] [Abstract][Full Text] [Related]
18. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
19. Current and future uses of positron emission tomography in breast cancer imaging.
Eubank WB; Mankoff DA
Semin Nucl Med; 2004 Jul; 34(3):224-40. PubMed ID: 15202103
[TBL] [Abstract][Full Text] [Related]
20. Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry.
Utech CI; Young CS; Winter PF
Eur J Nucl Med; 1996 Dec; 23(12):1588-93. PubMed ID: 8929312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]